← 產業報告目錄
Human iPSCs Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 117報告編號 APO-a0c91f34f1
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Human iPSCs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Human iPSCs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Human iPSCs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Human iPSCs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Human iPSCs include Sumitomo Dainippon Pharma, ReproCELL, Pluricell Biotech, Ncardia, Fujifilm Holding Corporation (CDI), Fate Therapeutics, Inc, Cell Inspire Biotechnology and Astellas Pharma Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human iPSCs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Human iPSCs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human iPSCs Market by Company
Sumitomo Dainippon Pharma
ReproCELL
Pluricell Biotech
Ncardia
Fujifilm Holding Corporation (CDI)
Fate Therapeutics, Inc
Cell Inspire Biotechnology
Astellas Pharma Inc
Human iPSCs Segment by Type
Skin
Blood Cells
Human iPSCs Segment by Application
Regenerative Medicine
Drug Development and Discovery
Academic Research
Toxicity Screening
Others
Human iPSCs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human iPSCs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human iPSCs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human iPSCs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human iPSCs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Human iPSCs by Type
2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
2.2.2 Skin
2.2.3 Blood Cells
2.3 Human iPSCs by Application
2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.3.2 Regenerative Medicine
2.3.3 Drug Development and Discovery
2.3.4 Academic Research
2.3.5 Toxicity Screening
2.3.6 Others
2.4 Assumptions and Limitations
3 Human iPSCs Breakdown Data by Type
3.1 Global Human iPSCs Historic Market Size by Type (2021-2026)
3.2 Global Human iPSCs Forecasted Market Size by Type (2027-2032)
4 Human iPSCs Breakdown Data by Application
4.1 Global Human iPSCs Historic Market Size by Application (2021-2026)
4.2 Global Human iPSCs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
5.1 Global Human iPSCs Market Perspective (2021-2032)
5.2 Global Human iPSCs Growth Trends by Region
5.2.1 Global Human iPSCs Market Size by Region: 2021 VS 2025 VS 2032
5.2.2 Human iPSCs Historic Market Size by Region (2021-2026)
5.2.3 Human iPSCs Forecasted Market Size by Region (2027-2032)
5.3 Human iPSCs Market Dynamics
5.3.1 Human iPSCs Industry Trends
5.3.2 Human iPSCs Market Drivers
5.3.3 Human iPSCs Market Challenges
5.3.4 Human iPSCs Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Human iPSCs Players by Revenue
6.1.1 Global Top Human iPSCs Players by Revenue (2021-2026)
6.1.2 Global Human iPSCs Revenue Market Share by Players (2021-2026)
6.2 Global Human iPSCs Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Human iPSCs Head Office and Area Served
6.4 Global Human iPSCs Players, Product Type & Application
6.5 Global Human iPSCs Manufacturers Established Date
6.6 Global Human iPSCs Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Human iPSCs Market Size (2021-2032)
7.2 North America Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
7.3 North America Human iPSCs Market Size by Country (2021-2026)
7.4 North America Human iPSCs Market Size by Country (2027-2032)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Human iPSCs Market Size (2021-2032)
8.2 Europe Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
8.3 Europe Human iPSCs Market Size by Country (2021-2026)
8.4 Europe Human iPSCs Market Size by Country (2027-2032)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Human iPSCs Market Size (2021-2032)
9.2 Asia-Pacific Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
9.3 Asia-Pacific Human iPSCs Market Size by Country (2021-2026)
9.4 Asia-Pacific Human iPSCs Market Size by Country (2027-2032)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Human iPSCs Market Size (2021-2032)
10.2 South America Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
10.3 South America Human iPSCs Market Size by Country (2021-2026)
10.4 South America Human iPSCs Market Size by Country (2027-2032)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Human iPSCs Market Size (2021-2032)
11.2 Middle East & Africa Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032
11.3 Middle East & Africa Human iPSCs Market Size by Country (2021-2026)
11.4 Middle East & Africa Human iPSCs Market Size by Country (2027-2032)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Sumitomo Dainippon Pharma
12.1.1 Sumitomo Dainippon Pharma Company Information
12.1.2 Sumitomo Dainippon Pharma Business Overview
12.1.3 Sumitomo Dainippon Pharma Revenue in Human iPSCs Business (2021-2026)
12.1.4 Sumitomo Dainippon Pharma Human iPSCs Product Portfolio
12.1.5 Sumitomo Dainippon Pharma Recent Developments
12.2 ReproCELL
12.2.1 ReproCELL Company Information
12.2.2 ReproCELL Business Overview
12.2.3 ReproCELL Revenue in Human iPSCs Business (2021-2026)
12.2.4 ReproCELL Human iPSCs Product Portfolio
12.2.5 ReproCELL Recent Developments
12.3 Pluricell Biotech
12.3.1 Pluricell Biotech Company Information
12.3.2 Pluricell Biotech Business Overview
12.3.3 Pluricell Biotech Revenue in Human iPSCs Business (2021-2026)
12.3.4 Pluricell Biotech Human iPSCs Product Portfolio
12.3.5 Pluricell Biotech Recent Developments
12.4 Ncardia
12.4.1 Ncardia Company Information
12.4.2 Ncardia Business Overview
12.4.3 Ncardia Revenue in Human iPSCs Business (2021-2026)
12.4.4 Ncardia Human iPSCs Product Portfolio
12.4.5 Ncardia Recent Developments
12.5 Fujifilm Holding Corporation (CDI)
12.5.1 Fujifilm Holding Corporation (CDI) Company Information
12.5.2 Fujifilm Holding Corporation (CDI) Business Overview
12.5.3 Fujifilm Holding Corporation (CDI) Revenue in Human iPSCs Business (2021-2026)
12.5.4 Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio
12.5.5 Fujifilm Holding Corporation (CDI) Recent Developments
12.6 Fate Therapeutics, Inc
12.6.1 Fate Therapeutics, Inc Company Information
12.6.2 Fate Therapeutics, Inc Business Overview
12.6.3 Fate Therapeutics, Inc Revenue in Human iPSCs Business (2021-2026)
12.6.4 Fate Therapeutics, Inc Human iPSCs Product Portfolio
12.6.5 Fate Therapeutics, Inc Recent Developments
12.7 Cell Inspire Biotechnology
12.7.1 Cell Inspire Biotechnology Company Information
12.7.2 Cell Inspire Biotechnology Business Overview
12.7.3 Cell Inspire Biotechnology Revenue in Human iPSCs Business (2021-2026)
12.7.4 Cell Inspire Biotechnology Human iPSCs Product Portfolio
12.7.5 Cell Inspire Biotechnology Recent Developments
12.8 Astellas Pharma Inc
12.8.1 Astellas Pharma Inc Company Information
12.8.2 Astellas Pharma Inc Business Overview
12.8.3 Astellas Pharma Inc Revenue in Human iPSCs Business (2021-2026)
12.8.4 Astellas Pharma Inc Human iPSCs Product Portfolio
12.8.5 Astellas Pharma Inc Recent Developments
13 Report Conclusion
14 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Human iPSCs Market Size by Type (2021-2026) & (US$ Million)
Table 6. Global Human iPSCs Revenue Market Share by Type (2021-2026)
Table 7. Global Human iPSCs Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 8. Global Human iPSCs Revenue Market Share by Type (2027-2032)
Table 9. Global Human iPSCs Market Size by Application (2021-2026) & (US$ Million)
Table 10. Global Human iPSCs Revenue Market Share by Application (2021-2026)
Table 11. Global Human iPSCs Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 12. Global Human iPSCs Revenue Market Share by Application (2027-2032)
Table 13. Global Human iPSCs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 14. Global Human iPSCs Market Size by Region (2021-2026) & (US$ Million)
Table 15. Global Human iPSCs Market Share by Region (2021-2026)
Table 16. Global Human iPSCs Forecasted Market Size by Region (2027-2032) & (US$ Million)
Table 17. Global Human iPSCs Market Share by Region (2027-2032)
Table 18. Human iPSCs Industry Trends
Table 19. Human iPSCs Industry Drivers
Table 20. Human iPSCs Industry Opportunities and Challenges
Table 21. Human iPSCs Market Restraints
Table 22. Global Top Human iPSCs Players by Revenue (US$ Million) & (2021-2026)
Table 23. Global Human iPSCs Revenue Market Share by Players (2021-2026)
Table 24. Global Human iPSCs Industry Players Ranking, 2024 VS 2025 VS 2026
Table 25. Global Key Players of Human iPSCs, Headquarters and Area Served
Table 26. Global Human iPSCs Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Human iPSCs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 31. North America Human iPSCs Market Size by Country (2021-2026) & (US$ Million)
Table 32. North America Human iPSCs Market Size by Country (2027-2032) & (US$ Million)
Table 33. Europe Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 34. Europe Human iPSCs Market Size by Country (2021-2026) & (US$ Million)
Table 35. Europe Human iPSCs Market Size by Country (2027-2032) & (US$ Million)
Table 36. Asia Pacific Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 37. Asia Pacific Human iPSCs Market Size by Region (2021-2026) & (US$ Million)
Table 38. Asia Pacific Human iPSCs Market Size by Country (2027-2032) & (US$ Million)
Table 39. South America Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 40. South America Human iPSCs Market Size by Country (2021-2026) & (US$ Million)
Table 41. South America Human iPSCs Market Size by Country (2027-2032) & (US$ Million)
Table 42. Middle East & Africa Human iPSCs Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 43. Middle East & Africa Human iPSCs Market Size by Country (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Human iPSCs Market Size by Country (2027-2032) & (US$ Million)
Table 45. Sumitomo Dainippon Pharma Company Information
Table 46. Sumitomo Dainippon Pharma Business Overview
Table 47. Sumitomo Dainippon Pharma Revenue in Human iPSCs Business (2021-2026) & (US$ Million)
Table 48. Sumitomo Dainippon Pharma Human iPSCs Product Portfolio
Table 49. Sumitomo Dainippon Pharma Recent Developments
Table 50. ReproCELL Company Information
Table 51. ReproCELL Business Overview
Table 52. ReproCELL Revenue in Human iPSCs Business (2021-2026) & (US$ Million)
Table 53. ReproCELL Human iPSCs Product Portfolio
Table 54. ReproCELL Recent Developments
Table 55. Pluricell Biotech Company Information
Table 56. Pluricell Biotech Business Overview
Table 57. Pluricell Biotech Revenue in Human iPSCs Business (2021-2026) & (US$ Million)
Table 58. Pluricell Biotech Human iPSCs Product Portfolio
Table 59. Pluricell Biotech Recent Developments
Table 60. Ncardia Company Information
Table 61. Ncardia Business Overview
Table 62. Ncardia Revenue in Human iPSCs Business (2021-2026) & (US$ Million)
Table 63. Ncardia Human iPSCs Product Portfolio
Table 64. Ncardia Recent Developments
Table 65. Fujifilm Holding Corporation (CDI) Company Information
Table 66. Fujifilm Holding Corporation (CDI) Business Overview
Table 67. Fujifilm Holding Corporation (CDI) Revenue in Human iPSCs Business (2021-2026) & (US$ Million)
Table 68. Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio
Table 69. Fujifilm Holding Corporation (CDI) Recent Developments
Table 70. Fate Therapeutics, Inc Company Information
Table 71. Fate Therapeutics, Inc Business Overview
Table 72. Fate Therapeutics, Inc Revenue in Human iPSCs Business (2021-2026) & (US$ Million)
Table 73. Fate Therapeutics, Inc Human iPSCs Product Portfolio
Table 74. Fate Therapeutics, Inc Recent Developments
Table 75. Cell Inspire Biotechnology Company Information
Table 76. Cell Inspire Biotechnology Business Overview
Table 77. Cell Inspire Biotechnology Revenue in Human iPSCs Business (2021-2026) & (US$ Million)
Table 78. Cell Inspire Biotechnology Human iPSCs Product Portfolio
Table 79. Cell Inspire Biotechnology Recent Developments
Table 80. Astellas Pharma Inc Company Information
Table 81. Astellas Pharma Inc Business Overview
Table 82. Astellas Pharma Inc Revenue in Human iPSCs Business (2021-2026) & (US$ Million)
Table 83. Astellas Pharma Inc Human iPSCs Product Portfolio
Table 84. Astellas Pharma Inc Recent Developments
Table 85. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Human iPSCs Product Image
Figure 5. Global Human iPSCs Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 6. Global Human iPSCs Market Share by Type: 2025 VS 2032
Figure 7. Skin Product
Figure 8. Blood Cells Product
Figure 9. Global Human iPSCs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 10. Global Human iPSCs Market Share by Application: 2025 VS 2032
Figure 11. Regenerative Medicine Product
Figure 12. Drug Development and Discovery Product
Figure 13. Academic Research Product
Figure 14. Toxicity Screening Product
Figure 15. Others Product
Figure 16. Global Human iPSCs Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 17. Global Human iPSCs Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 18. Global Human iPSCs Market Share by Region: 2025 VS 2032
Figure 19. Global Human iPSCs Market Share by Players in 2025
Figure 20. Global Human iPSCs Manufacturers Established Date
Figure 21. Global Top 5 and 10 Human iPSCs Players Market Share by Revenue in 2025
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 23. North America Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 24. North America Human iPSCs Market Share by Country (2021-2032)
Figure 25. United States Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 26. Canada Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 27. Mexico Human iPSCs Market Share by Country (2021-2032)
Figure 28. Europe Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 29. Europe Human iPSCs Market Share by Country (2021-2032)
Figure 30. Germany Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 31. France Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 32. U.K. Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 33. Italy Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 34. Spain Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 35. Russia Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 36. Netherlands Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 37. Nordic Countries Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 38. Asia-Pacific Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 39. Asia-Pacific Human iPSCs Market Share by Country (2021-2032)
Figure 40. China Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 41. Japan Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 42. South Korea Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 43. India Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 44. India Human iPSCs Market Share by Country (2021-2032)
Figure 45. Australia Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 46. China Taiwan Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 47. Southeast Asia Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 48. South America Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 49. South America Human iPSCs Market Share by Country (2021-2032)
Figure 50. Brazil Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 51. Argentina Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 52. Chile Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 53. Colombia Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 54. Peru Human iPSCs Market Size YoY Growth (2021-2032) & (US$ Million)
Figure 55. Sumitomo Dainippon Pharma Revenue Growth Rate in Human iPSCs Business (2021-2026)
Figure 56. ReproCELL Revenue Growth Rate in Human iPSCs Business (2021-2026)
Figure 57. Pluricell Biotech Revenue Growth Rate in Human iPSCs Business (2021-2026)
Figure 58. Ncardia Revenue Growth Rate in Human iPSCs Business (2021-2026)
Figure 59. Fujifilm Holding Corporation (CDI) Revenue Growth Rate in Human iPSCs Business (2021-2026)
Figure 60. Fate Therapeutics, Inc Revenue Growth Rate in Human iPSCs Business (2021-2026)
Figure 61. Cell Inspire Biotechnology Revenue Growth Rate in Human iPSCs Business (2021-2026)
Figure 62. Astellas Pharma Inc Revenue Growth Rate in Human iPSCs Business (2021-2026)
提及公司
Sumitomo Dainippon PharmaReproCELLPluricell BiotechNcardiaFujifilm Holding Corporation (CDI)Fate Therapeutics, IncCell Inspire BiotechnologyAstellas Pharma Inc
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們